Оптимізація лікування хворих хронічною серцевою недостатністю ішемічного походження в поєднанні з цукровим діабетом 2-го типу на підставі вивчення маркерів фіброзу галектина 3, матриксної металопротеїнази 1

123. Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. / [H. Wen, D. Gris, Y. Lei et al.] // Nat Immunol. - 2011. - №12. - P. 408-415.

124. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes./ [S. Zoungas, J. Chalmers, B. Neal et al.] // The New England Journal of Medicine. - 2014. - № 371(15). - P. 1392-1406.

125. Galectin-3 activates PPARг and supports white adipose tissue formation and high-fat diet-induced obesity / [J. Baek, S. Kim, H. Kang et al.]. // Endocrinology. - 2015. - №156 (11). - P. 147-56.

126. Galectin-3 and Hypertensive Heart Disease / [C. Cuspidi, M. Tadic, C. Sala et al.]. // The Journal of Clinical Hypertension. - 2015. - Р. 13.

127. Galectin-3 deficiency accelerates high-fat diet-induced obesity and amplifies inflammation in adipose tissue and pancreatic islets. / [NN Pejnovic, JM Pantic, IP Jovanovic et al] // Diabetes - 2013- №62(6) - P. 1932-1944

128. Galectin-3 Deficiency Accelerates High-Fat Diet-Induced Obesity and Amplifies Inflammation in Adipose Tissue and Pancreatic Islets/ [N. Nada, Pejnovic, M. Jelena et al] // Diabetes - 2013 - № 62 - P.1932-1944.

129. Galectin-3 deficiency protects pancreatic islet cells from cytokine-triggered apoptosis in vitro. / [T Saksida, I Nikolic, M Vujicic et al ] // J Cell Physiol- 2014-№7 - P. 1568-1576.

130. Galectin-3 in diabetic patients. / [G Pugliese, C Iacobini, C Ricci et al] // Clin Chem Lab Med - 2014 - №52(10) - P. 1413-1423.

131. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community / [J. Ho, C. Liu, A. Lyass et al.]. // J Am Coll Cardiol. - 2012. - №60 (14). - Р. 1249-1256.

132. Galphas-biased beta2-adrenergic receptor signaling from restoring synchronous contraction in the failing heart / [K. Chakir, C. Depry, V. Dimaano et al.]. // Sci Transl Med. - 2011. - №3. - Р. 100-188.

133. Guillermo Torre-Amione Cellular Evidence of Reverse Cardiac Remodeling Induced by Cardiac Resynchronization Therapy / [C. Orrego, N. Nasir, G. Oliveira et al.]. // Congestive Heart Failure. - 2011. - №17(3). - Р. 140-146.

134. Hashmi S. Galectin-3 is expressed in the myocardium very early post-myocardial infarction. / Hashmi S, Al-Salam S. // Cardiovasc Pathol. - 2015 - № 24(4) - Р. 213-23.

135. Heart disease and stroke statistics-2015 update a report from the american heart association. / [D Mozaffarian, EJ Benjamin, DK Arnett et al] // Circulation.- 2015.- №131.- Р. 29-322.

136. Heart failure with systolic dysfunction complicating acute myocardial infarction - differential outcomes but similar eplerenone efficacy by ST-segment or non- ST-segment elevation: a post hoc substudy of the EPHESUS trial / [S. Carillo, Y. Zhang, R. Fay et al.]. // Arch. Cardiovasc. Dis. - 2014. - №107. - Р. 149-157.

137. Heather LC. Metabolism, hypoxia and the diabetic heart./ LC Heather, K Clarke // J Mol Cell Cardiol - 2011 - № 50 - Р.598-605.

138. Heterogeneity in MT1-MMP activity with ischemia-reperfusion and previous myocardial infarction: relation to regional myocardial function. / [J. Dixon, W. Gaillard, W. Rivers et al.]. // Am J Physiol Heart Circ Physiol. - 2010. - №299. - Р. 1947-1958.

139. Hyperglycemic myocardial damage is mediated by proinflammatory cytokine: macrophage migration inhibitory factor. / X.Y. Yu, H.M. Chen, J.L. Liang et al. // PLoS One. - 2011. - № 6 (1). - e16239.

140. Hysiological and pathological left ventricular hypertrophy of comparable degree is associated with characteristic differences of in vivo hemodynamics.// Am J Physiol Heart Circ Physiol. - 2015 - ajpheart.00588.

141. IDF Diabetes Atlas / International Diabetes Federation. - 7th ed. - Brussels : International Diabetes Federation, 2015. - 144 p.

142. IDF Global Guideline for Managing Older People with Type 2 Diabetes. / A. Sinclair, T. Dunning, S. Colagiuri. // International Diabetes Federation. - 2013. - Р. 1-94.

143. IgE influences the number and function of mature mast cells, but not progenitor recruitment in allergic pulmonary inflammation/ [CB Mathias, EJ Freyschmidt, B Caplan et al.] // J Immunol - 2009 - №182 - P.2416-2424.

144. Impact of clinical and echocardiographic response to cardiac resynchronization therapy on long-term survival / [M. Bertini, U. Hцke, R. van Bommel et al.]. // Eur Heart J Cardiovasc Imaging. - 2013. - №14(8). - Р. 774-781.

145. Impact of ESC/ACCF/AHA/WHF universal definition of myocardial infarction on mortality at 10 years / F. Costal, J. Ferreiral. // EuroHeart J. - 2012. - №33 (20). - Р. 2544 - 2550.

146. Impact of mineralocorticoid receptor antagonists on changes in cardiac structure and function of left ventricular dysfunction: a meta-analysis of randomized controlled trials /[ X. Li, Y. Qi, S. Zhang. et al] // Circ Heart Fail. - 2013 - №6(2) - Р.156-65.

147. Increased adiposity, dysregulated glucose metabolism and systemic inflammation in Galectin-3 KO mice. / [Pang J, Rhodes DH, Pini M et al] // PLoS One - 2013- №8(2) - e57915.

148. Increased extracellular volume and altered mechanics are associated with LVH in hypertensive heart disease, not hypertension alone / [S. Kuruvilla, R. Janardhanan, P. Antkowiak et al.].// JACC Cardiovasc Imaging. - 2015 - №8 - Р.172-180.

149. Increased levels of galectin-3 were associated with pre diabetes and diabetes: new risk factor? J Endocrinol Invest 2014 Alexander E Berezin, Is Elevated Circulating Level of Galectin-3 A Marker with Diagnostic and Predictive Value in Diabetic Patients? / [H. Yilmaz, M. Cakmak, O. Inan et al.] // Heart Health Open Access - 2015 - № 2 - P.110

150. Inflammasome is a central player in the induction of obesity and insulin resistance. / [R. Stienstra, JA. van Diepen, CJ. Tack et al.] // Proc Natl Acad Sci USA. - 2011 - 108:15324-15329.

151. Influence of left ventricular lead position relative to scar location on response to cardiac resynchronization therapy: a model study./ PR Huntjens, J Walmsley, S Ploux et al. // Europace. - 2014 №16(4) :iv62-iv68.

152. International Diabetes Federation.Diabetes Atlas. - 6 th ed. - Brussels, Belgium International Diabetes Federation - 2013 -№ 116 - р.35.

153. Interstitial myocardial fibrosis is associated with arrhythmic sudden death / [Z.H. Tseng, Ursel lP., ColburnB. et al.] // J. Amer. Coll. Cardial.- 2013.- № 61 (10 S).

154. Intra-left ventricular electromechanical asynchrony. A new independent predictor of severe cardiac events in heart failure patients / [H. Bader, S. Garrigue, S. Lafitte et al.]. // J Am Coll Cardiol. - 2004. - №43. - P. 248-256.

155. Invasive acute hemodynamic response to guide left ventricular lead implantation predicts chronic remodeling in patients undergoing cardiac resynchronization therapy / [S. Duckett, M. Ginks, A. Shetty et al.]. // //J Am Coll Cardiol. - 2011. - №58. - Р. 1128-1136.

156. Ivashkiv LB. Regulation of type i interferon responses./ LB Ivashkiv, LT Donlin // Nat Rev Immunol.- 2014. - № 14.- P.36-49.

157. J.Shirani et al. Usefuiness of the Electrocardiogram and Echocardiogram in predicting the amount of interstitial myocardial collagen in endomyocardial biopsy specimens of patients with chronic heart failure / J.Shirani et al //Am. J.Cardiol. - 1992. - №69 -Р.1502.

158. Janicki J. Gender differences in non-ischemic myocardial remodeling: are they due to estrogen modulation of cardiac mast cells and/or membrane type 1 matrix metalloproteinase. / J. Janicki, F. Spinale, S. Levick. // Pflugers Arch. - 2013 - № 465(5) - Р. 687-97

159. Jin Q. Serum galectin-3: a risk factor for vascular complications in type 2 diabetes mellitus / Q. Jin, Y. Lou, T. Li. // Chin Med J (Engl). - 2013 - №126(11) - Р.2109-15

160. Kengne AP. Multiple risk factor interventions and inflammatory biomarkers in high risk individuals with type 2 diabetes./ AP Kengne, E Sobngwi, J. Chalmers // Diabetes Res Clin Pract. - 2012 - № 95 - P.386-388.

161. Khidir MJ. Mechanical dyssynchrony in patients with heart failure and reduced ejection fraction: how to measure? / MJ Khidir ,V Delgado NA Marsan // Curr Opin Cardiol. - 2016. - Р.54.

162. Kirk J. Electromechanical Dyssynchrony and Resynchronization of the Failing Heart /J. Kirk, D. Kass // Circ Res. - 2013. - №113(6) - 10.1161

163. Kirk JA.Cellular and Molecular Aspects of Dyssynchrony and Resynchronization Card Electrophysiol Clin. / JA Kirk ,DA Kass //- 2015 - №7(4) - P.585-597.

164. Lajiness J. Origin, development, and differentiation of cardiacfibroblast. / J. Lajiness, S. Conway. // J Mol Cell Cardiol. - 2014. - №70. - Р. 2-8.

165. Lang RM. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the american society of echocardiography and the European association of cardiovascular imaging.[ RM Lang, LP Badano, V Mor-Avi et al.]//Eur Heart J Cardiovasc Imaging. - 2015 - №16(3).

166. Langenberg C. Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1-9 million people. / C. Langenberg , E Rapsomaniki // Lancet Diabetes Endocrinol. - 2015. - №3 - Р.105-113.

167. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters / [M. Feuerer, L. Herrero, D. Cipolletta et al.]. // Nat Med. - 2009. - №15. - Р. 930-939.

168. Left ventricular dyssynchrony predicts response to cardiac resynchronization therapy / D. Knappe, A. C. Pouleur, A. M. Shah et al // Circ. Heart Fail. - 2011. - № 4. - P. 33-40.

169. Leitman M. Two-dimensional strain-a novel software for real-time quantitative echocardiographic assessment of myocardial function [Text]/ M. Leitman, P. Lysyansky, S. Sidenko et al. // J. Am. Soc.Echocardiogr. - 2004. - Vol.17. - Р. 1021-1029.

170. Leong DP1. Effects of myocardial fibrosis and ventricular dyssynchrony on response to therapy in new-presentation idiopathic dilated cardiomyopathy: insights from cardiovascular magnetic resonance and echocardiography. [Leong DP1, Chakrabarty A, Shipp N et al.] //Eur Heart J. - 2012.- № 33 (5) P. 640-648.

171. Leung M. Rationale and design of a randomized trial on the impact of aldosterone antagonism on cardiac structure and function in diabetic cardiomyopathy /[ M. Leung, V.W.Wong, S. Heritier et al] // Cardiovasc. Diabetol. - 2013. - V. 12. - P. 139.

172. Linde, C. Cardiac resynchronization therapy (CRT): clinical trials, guidelines, and target populations / C.Linde, K.Ellenbogen, F.A.McAlister //Hearth Rhytm. - 2012, vol.9 -№85. - Р.3-13.

173. Long-term protection and mechanism of pacing-induced postconditioning in the heart / [F. Babiker, I. Lorenzen-Schmidt, E. Mokelke et al.]. // Basic Res Cardiol. - 2010. - №105. - Р. 523-33.

174. Low serum galectin-3 concentrations are associated with insulin resistance in patients with type 2 diabetes mellitus. / [T Ohkura, Y Fujioka, R Nakanishi et al.]// Diabetol Metab Syndr. - 2014; - №6(1) P. 106.

175. Lumeng CN. Inflammatory links between obesity and metabolic disease / CN Lumeng, AR Saltiel. // J Clin Invest - 2011 - №121 - Р.2111-2117

176. MADIT-CRT Investigators. Effectiveness of Cardiac Resynchronization Therapy by QRS Morphology in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT). / [W. Zareba ,H. Klein , I. Cygankiewicz et al.] // Circulation. - 2011. - №123(10). - Р.1061-1072.

177. Mann DL. Innate immunity and the failing heart: the cytokine hypothesis revisited. / DL Mann //Circ Res. - 2015. - №116(7). - P. 1254-68.

178. Mast cells and inflammation. / [Theoharides TC, Alysandratos KD, Angelidou A et al. ] // Biochim Biophys Acta. - 2012. - 1822.- Р. 21-33.

179. McCullough PA. Galectin-3: a novel blood test for the evaluation and management of patients with heart failure. / PA McCullough, A Olobatoke, TE Vanhecke // Rev Cardiovasc Med - 2011 - 12(4) - P.200-210.

180. Mechanical dyssynchrony and deformation imaging in patients with functional mitral regurgitation / [I. Rosa, C. Marini, F. Ancona et al.]. // World J Cardiol. - 2016 - № 8(2) - Р. 146-162.

181. Megumi E.Diabetes influences cardiac extracellular matrix remodelling after myocardial infarction and subsequent development of cardiac dysfunction /E. Megumi , Xu Guoxiong, Li Ren-Ke .// J Cell Mol Med. - 2012 - №16(12) - P. 2925-2934.

182. Mice with tissue inhibitor of metalloproteinases 4 (Timp4) deletion succumb to induced myocardial infarction but not to cardiac pressure overload / [I. Koskivirta, Z. Kassiri, O. Rahkonen et al.]. // J Biol Chem. - 2010 - №285 - P.24487-93.

183. MikiT. Diabetic cardiomyopathy: pathophysiology and clinical features. / T Miki, S Yuda, H Kouzu // HeartFailRev. - 2013. - р.60.

184. Morphology and contractility of cardiac myocytes in early stages of streptozotocin-induced diabetes mellitus in rats / M.Cagalinec, I. Waczulнkovб, O. Uliиnб, D. Chorvat. // Physiol Res. - 2013. - №62. - Р. 489-501.

185. Motiwala S. R. Serial measurement galectin-3 in patients with chronic heart failure: results from ProBNPOutpatient Tailored Chronic Heart Failure Therapy (PROTECT) study / S. R. Motiwala, J. Szymonifka [et al.] // Eur. J. Heart Fail. - 2013. - Vol. 15. - P. 1157-1163.

186. Muraoka H. Reverse remodeling achieved by combination therapy with high-dose beta blocker and cardiac resynchronization / H. Muraoka, T. Imamura, K. Kinugawa // Int. Heart. J. - 2015. - № 18.

187. Myocardial fibrosis: biomedical research from bench to bedside. / [M. Gyцngyцsi, J. Winkler, I. Ramos et al.]. // Eur J Heart Fail. - 2017. - №19. - Р. 177-191.

188. Myocardial Regional Interstitial Fibrosis is Associated With Left Intra-Ventricular Dyssynchrony in Patients With Heart Failure: A Cardiovascular Magnetic Resonance StudyKirk / [L. Wu, C. Juang, J. Wang et al.]. // Electromechanical dyssynchrony and resynchronization of the failing heart. Circ Res. - 2013. - №113. - Р. 765-776.

189. Myocardial Remodeling in Diabetic Cardiomyopathy Associated with Cardiac Mast Cell Activation / [Z. Huang, Q. Jin, M. Fan et al.]. // PLoS ONE. - 2013. - №8(3): e60827.

190. Myocardial systolic and diastolic consequences of left ventricular mechanical dyssynchrony in heart failure with normal left ventricular ejection fraction / [DA Morris, AV Pйrez, F. Blaschke et al] //Eur Heart J Cardiovasc Imaging. - 2012.- №13. - Р.556-567.

191. Nagarajan V. The role of aldosterone receptor antagonists in the management of heart failure: an update / V. Nagarajan, M. Chamsi-Pasha, W.H. Tang // Cleve. Clin. J. Med. - 2012. - V. 79. - P. 631-639.

192. National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States.Atlanta, GA:Centers for Disease Control and Prevention - 2011. - P. 76 -78.

193. Newer biomarkers in heart failure / [R. De Boer, L. Daniels, A. Maisel et al.]. // Eur J Heart Fail. - 2015. - Р. 54.

194. Nirala BK. Glycated serum albumin stimulates expression of endothelial cell specific molecule-1 in human umbilical vein endothelial cells: Implication in diabetes mediated endothelial dysfunction. / BK Nirala, V Perumal, NK Gohil // Diab Vasc Dis Res. 2015 pii: 1479164115583192.

195. Novel inflammatory markers in hyperlipidemia: clinical implications. / [A Papapanagiotou, G Siasos, E Kassi et al ] // Curr Med Chem. - 2015.

196. Novel therapeutic targets of metformin: metabolic syndrome and cardiovascular disease / [R. Ladeiras-Lopes, R. Fontes-Carvalho, N. Bettencourt et al.].// Expert Opin Ther Targets - 2015 - № 19 - Р.869-877.

197. Occurrence, fate and consequences of ventricular conduction abnormalities after transcatheter aortic valve implantation. / [P. Houthuizen, R. van der Boon, M. Urena et al.]. // EuroIntervention. - 2014. - №9. - Р. 1142-1150.

198. Overexpression of human C-reactive protein exacerbates left ventricular remodeling in diabetic cardiomyopathy /[ Y Mano, T Anzai, H Kaneko, et al.] .// Circ J. 2011 - №75 (7). - P. 1717-1727.

199. Pacing-induced dys-synchrony preconditions rabbit myocardium against ischemia/reperfusion injury. / [W.Y. Vanagt, R.N. Cornelussen, Q.P. Poulina et al.] // Circulation.- 2006.- №114(1). - P. 264-9.

200. Past, present and future of cardiac resynchronization / [C. Daubert, S. Cazeau, P. Ritter et al.]. // Arch Cardiovasc Dis. - 2012. - №105. - Р. 291-299.

201. Paulus WJ. Cytokines and heart failure. Heart Fail Monit. / WJ Paulus // PLoS One. - 2014. - №1. - P. 50-56.

202. Paulus WJ. Novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation./ WJ Paulus, C. A Tschцpe // J Am Coll Cardiol - 2013 - №23 - P. 263-271.

203. Plasma galectin 3 and heart failure risk in the Physicians' Health Study / [L. Djoussй, C. Matsumoto, A. Petrone et al.]. // Eur J Heart Fail. - 2013. - №43. - С. 73.

204. Plasma galectin 3 and heart failure risk in the Physicians' Health Study./ [C. Matsumoto, A. Petrone et al.] // Eur J Heart Fail.2014. - №16 - P. 350-354.

205. Predictive value of galectin-3 for incident cardiovascular disease and heart failure in the population-based FINRISK 1997 cohort. / [A. Jagodzinski, A. Havulinna, S. Appelbaum et al.].// Int J Cardiol. - 2015. - № 192. - Р. 33-39.

206. Pressure overload-dependent membrane type 1-matrix metalloproteinase induction: relationship to LV remodeling and fibrosis / M.R. Zile //Am J Physiol Heart Circ Physiol. - 2013. - №341(9). - P. 1359-39.

207. Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH. / [A.R. Van der Velde, L. Gullestad, T. Ueland et al] // Circ Heart Fail - 2013.- № 6(2). - P. 219-226.

208. Prognostic value of late gadolinium enhancement in hypertensive patients with known or suspected coronary artery disease / [R. Krittayaphong, T. Boonyasirinant, V. Chaithiraphan et al.] // Int J Cardiovasc Imaging. - 2010. - 26 Suppl 1:123-13164.

209. Prognostic value of plasma galectin-3 levels in patients with coronary heart disease and chronic heart failure. / X. Yu, Y. Sun, Y. Zhao et al. // IntHeartJ. - 2015 - 56(3) - P. 314-318.

210. Progressive induction of left ventricular pressure overload in a large animal model elicits myocardial remodeling and a unique matrix signature./ [W.M. Yarbrough, R. Mukherjee, R.E. Stroud et al.] // J Thorac Cardiovasc Surg. - 2012 - №143 - P.215-223.

211. Protein kinase C promotes cardiac fibrosis and heart failure by modulating galectin-3 expression. / [X. Song, X. Qian, M. Shen et al.] // Biochim Biophys Acta - 2015. - 1853(2). -P. 513-521.

212. Qiangjun Cai M.D.Left Ventricular Dyssynchrony by Three-Dimensional Echocardiography: / M.D. Qiangjun Cai, M.D. Masood Ahmad // Current Understanding and Potential Future Clinical Applications Echocardiography. - 2015. - V 32. - P. 1299-1306.

213. Rat model of exercise-induced cardiac hypertrophy: hemodynamic characterization using left ventricular pressure-volume analysis. / [T Radovits, A Olбh, Б Lux. et al] // Am J Physiol Heart Circ Physiol. - 2013. - № 305(1). - P. 124-134.

214. Recent advances in understanding the biochemical and molecular mechanism of diabetic cardiomyopathy. /[ Liu JW, Liu D, Cui KZ et al.] //Biochem Biophys Res Commun. - 2012. - № 427. - Р. 441-443.

215. Recommendations for the echocardiographic assessment of native valvular regurgitation: an executive summary from the European Association of Cardiovascular Imaging / [P. Lancellotti, C. Tribouilloy, A. Hagendorff et al.] // Eur. Heart J. Cardiovasc. Imaging.- 2013.- Vol. 14 (7).- P. 611?644.

216. Recycling of galectin-3 in epithelial cells. / [E. Hцnig, K. Schneider, R. Jacob et al.]. // Eur J Cell Товарbiol.. - 2015. - С. S0171 - 9335(15)00050-3.

217. Regression of myocardial hypertrophy after a orticvalvere placement: fasterin women? / [G Petrov, V Regitz-Zagrosek, E. Lehmkuhl et al] // Circulation.- 2010. - №122. -P. 23-28.

218. Relationship of echocardiographic dyssynchrony to long-term survival after cardiac resynchronization therapy / [J. Gorcsan, O. Oyenuga, P. Habib et al.]. // Circulation. - 2010. - №122. - Р. 1910-1918.

219. Replacement and reactive myocardial fibrosis in idiopathic dilated cardiomyopathy: comparison of magnetic resonance imaging with right ventricular biopsy. / [S Schalla, SC Bekkers, R Dennert et al. ]// Eur J Heart Fail - 2010 - №12 - P. 227-231.

220. Repolarization Alternans and Ventricular Arrhythmia in a Repaired Tetralogy of Fallot Animal Model / [S. Chiu, C. Tsai, et al.]. // J Am Heart Assoc. - 2015. - №11.

221. Repolarization changes in patients with heart failure receiving cardiac resynchronization therapy-signs of cardiac memory. / [L. Wecke, C.J. van Deursen, L. Bergfeldt et al.] // J Electrocardiol. - 2011. - № 44. - P. 590-598.

222. Results of the Predictors of Response to CRT (PROSPECT) trial / [E. Chung, A. Leon, L. Tavazzi et al.]. // Circulation. - 2008. - №117 (20). - С. 2608 -2616.

223. Results of the Prospective Minnesota Study of ECHO/TDI in Cardiac Resynchronization Therapy (PROMISE-CRT) study / [A. Bank, C. Kaufman, A. Kelly et al.]. // J Card Fail. - 2009. - №15. - С. 401-409.

224. Rodriguez-Poncelas A. Affiliated with Comparison of different vascular risken gines in the identification of type 2 diabetes patients with high cardio vascular risk/BMC / A. Rodriguez-Poncelas, G. Coll-de Tuero. // Cardiovascular Disorders. - 2015. - №15. - P. 121.

225. Role of biomarkers in cardiac structure phenotyping in heart failure with preserved ejection fraction / [E. D'Elia, M. Vaduganathan, M. Gori et al.]. // European Journal of Heart Failure. - 2015. - V 17. - Р. 1231-1239.

226. Role of nuclear factor кB in diabetic cardiomyopathy. /[ O. Lorenzo, В. Picatoste, Ares-Carrasco et al.] // Mediators Inflamm. - 2011: 652097.

227. Rosen MR. Cardiac memory: The slippery slope twixt normalcy and pathology. / MR Rosen , L Bergfeldt // Trends Cardiovasc Med. - 2015. - № 25(8). - P. 687-96.

228. Ruschitzka F. Cardiac-resynchronization therapy in heart failure with a narrow QRS complex / F. Ruschitzka, W.T.Abraham, J.P.Singh, // N.Engl.J.Med.- 2013 - vol.10 - №15 - P.1395-1408.

229. Schreurs R. Pathophysiology of dyssynchrony: of squirrels and broken bones Neth Heart J./ R. F, . Schreurs R, F.W Prinzen // - 2016 - №24(1) -P. 4-10.

230. SEARCH for Diabetes in Youth Study Group. Prevalence of overweight and obesity in youth with diabetes in USA: the SEARCH for Diabetes in Youth study. / [L.L. Liu, J.M. Lawrence, C. Davis et al.] // Pediatr Diabetes. - 2010. - №11. - Р.4-11.

231. Searching for new mechanisms of myocardial fibrosis with diagnostic and orther apeutic potential / [S. Heymans, A. Gonzбlez, A. Pizard et al.]. // Eur J Heart Fail. - 2015. - №17 (8). - С. 764-771.

232. Septal rebound stretch reflects the functional substrate to cardiac resynchronization therapy and predicts volumetric and neurohormonal response / [B. De Boeck, A. Teske, M. Meine et al.]. // Eur J Heart Fail. - 2009. - №11. - С. 863-871.

233. Serum galectin-3 levels in women with PCOS / [H. Yilmaz, H.T. Celik, O. Ozdemir et al.] .// J Endocrinol Invest - 2014 - 201437(2). P. 181-187.

234. Shirani J. Usefulness of the Electrocardiogram and Echocardiogram in predicting the amount of interstitial myocardial collagen in endomyocardial biopsy specimens of patients with chronic heart failure / J.Shirani, R.Pick, Y. Quo // Am. J. Cardiol. - 1992. - V. 69. - P. 1502.

235. Simon J.A. What's new in hormone replacement therapy: focus on transdermal estradiol and micronized progesterone. / J.A. Simon // Climacteric.- 2012. - №15. - P.3-10.

236. Simultaneous determination of serum galectin-3 і -4 levels detects metastases in colorectal cancer patients. Cell Oncol (Dordr) - V 36(1). - P. 9-13.

237. Smiseth O.A. The role of echocardiography in quantification of left ventricular dyssynchrony: state of the art and future directions. / O.A. Smiseth, K. Russell, H. Skulstad //Eur Heart J Cardiovasc Imaging. - 2012. -№ 13(1). - P.61-68.

238. Structural myocardial alterations in diabetes and hypertension: the role of galectin-3. / [J.P. Seferovic, N.M. Lalic, F. Floridi et al.] // Clin Chem Lab Med. - 2014. - №52(10). - P. 1499-505.

239. Successful reduction of intraventricular asynchrony is associated with superior response to cardiac resynchronization therapy / [H. Dreger, A. Borges, G. Baumann et al.]. // Cardiovasc Ultrasound. - 2010. - №8. - Р. 35.

240. Sundell, J. The effects of cardiac resynchronization therapy on left ventricular function, myocardial energetics, and metabolic reserve in patients with dilated cardiomyopathy and heart failure / J. Sundell, E. Engblom, J. Koistinen // J. Am. Coll.Cardiol. - 2004. - Vol. 43. - P. 1027-1033.

241. Superoxide production of NAD(P)H oxidase and mitochondria is increased in genetically obese and hyperglycemic rat heart and aorta before the development of cardiac dysfunction. The role of glucose-6-phosphate dehydrogenase-derived NADPH. / [S. Serpillon, BC. Floyd, RS. Gupte et al] // Am J Physiol Heart Circ Physiol. - 2009. - № 297.- P.153-162.

242. Targeted disruption of the galectin-3 gene results in decreased susceptibility to multiple low dose streptozotocin-induced diabetes in mice. / [E.P. Mensah-Brown, Z. Al Rabesi, A. Shahin et al] // Clin Immunol. - 2009. - №130(1). - P. 83-88.

243. Temporal expression of galectin-3 following myocardial infarction. / [TD Milner, AC Viner, AC MacKinnon et al] // Acta Cardiol. - 2014. - №69(6). - P. 595-602.

244. The acute effects of changes to AV delay on blood pressure and stroke volume: potential implications for design of pacemaker optimization protocols. / [C. Manisty, A. Al-Hussaini, B. Unsworth et al.] // Circ Arrhythm Electrophysiol.- 2012. - №5. - P.122-130.

245. The association between galectin-3 and clinical parameters in patients with first acute myocardial infarction treated with primary percutaneous coronary angioplasty. / [I. Szadkowska, RN. Wlazeі, M .Migaіa et al.] // Cardiol J. - 2013. - №20(6). -P. 577-582.

246. The influence of right ventricular stimulation on acute response to cardiac resynchronisation therapy. /[ J. Neth Heart, L. Wu, G.J. de Roest et al] // Neth Heart J. - 2016 - №24(1). - P. 66-72.

247. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. / [B. Vandanmagsar, Y.H. Youm, A. Ravussin et al.] // Nat Med. - 2011.- №17. - P. 179-188.

248. The role of galectin-3 and galectin-3-binding protein in venous thrombosis / [P. Elise, S. Wrobleski, E. Shea et al.] // Blood. - 2015. - №125 (11). - Р. 1813 - 1821.

249. The role of inflammation in diabetic cardiomyopathy / [S Nunes, E Soares, FC Pereira et al ] // International Journal of Interferon, Cytokine and Mediator Research. - 2012. - Vol 4. - P. 59-73.

250. The Soft and Hard Heartedness of Cardiac Fibroblasts: Mechanotrans duction Signaling Path ways in Fibrosis of the Heart / [K. Herum, I. Lunde, A. McCulloch et al.] // J Clin Med. - 2017. - №6. - Р. 53.

251. The Soft- andHard-Heartednessof Cardiac Fibroblasts: MechanotransductionSignalingPathwaysin Fibrosis of the Heart / [L. . Djoussй, K. Herum, L. IdaG et al.]. // JClinMed. - 2017. - №53.

252. TIMP2 deficiency accelerates adverse post-myocardial infarction remodeling because of enhanced MT1-MMP activity despite lack of MMP2 activation./ [V Kandalam, R Basu, T Abraham et al.]// Circ Res. - №2010. - №106. - P.796-808.

253. TNF-alpha Stimulates MMP-2 and MMP-9 Activities in Human Corneal Epithelial Cells via the Activation of FAK/ERK Signaling. / [Y.N. Yang, F. Wang, W. Zhou et al.] // Ophthalmic Res. - 2012. - №48. - P.165-170.

254. Tomographic left ventricular volumetric emptying analysis by real-time 3-dimensional echocardiography: influence of left ventricular dysfunction with and without electrical dyssynchrony / [S. De Castro, F. Faletra, E. Di Angelantonio et al.]. // Circ Cardiovasc Imaging. - 2008. - №1 (1). - Р.41-49.

255. Topcat Investigators. Treatment Of Preserved Cardiac Function Heart Failure with an Aldosterone anTagonist (TOPCAT). / [M.A. Pfeffer, S McKinlay., B. Pitt et al.] // Program and abstracts of the American Heart Association Scientific Sessions 2013. - Dallas. - 2013.

256. Transient outward potassium channel regulation in healthy and diabetic hearts. / [M. Gallego, A. Alday, J. Urrutia et al.]. // Can J Physiol Pharmacol. - 2009. - №87. - С. 77-83.

257. Transseptal conduction as an important determinant for cardiac resynchronization therapy, as revealed by extensive electrical mapping in the dyssynchronous canine heart. / [M. Strik, CJM. van Deursen, LB. van Middendorp et al.] // Circ Arrhythm Electrophysiol. - 2013. - №6. - P. 682-689.

258. Ukkonen H. Effect of cardiac resynchronization on myocardial efficiency and regional oxidative metabolism / H. Ukkonen, R. S. Beanlands, I. G. Burwashn // Circulation. - 2003. - Vol. 107. - Р. 28-31.

259. Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction. / Heart Failure Society of America Guidelines Committee / [J. Butler, J. Ezekowitz, S. Collins et al.]. // J Card Fail. - 2012. - №18. - Р. 265-281.

260. Van Veldhuisen. Implementation of device therapy (cardiac resynchronization therapy and implantable cardioverter defibrillator) for patients with heartfailure in Europe: changes from 2004 to 2008 / D. J. Van Veldhuisen, A. H. Maass, S. G. Priori // Eur. J. Heart Fail. - 2009. - Vol. 11. - P. 1143-1151.

261. Vitarelli, A. Echocardiographic assessment of ventricular asynchrony in dilated cardiomyopathy and congenital heart disease: tools and hopes / A. Vitarelli, P. Franciosa, Y. Conde et al. // J. Am. Soc. Echocardiogr. - 2005. - Vol. 18. - p. 1424-1439.

262. Voulgari.С. Diabetic cardiomyopathy: from the pathophysiology of the cardiacmyocytesto current diagnosis and management strategies / C. Voulgari, D. Papadogiannis, N. Tentolouris // Vasc. Health Risk Manag. - 2010. - Vol. 6. - P. 883-903.

263. Wang H. Real time three-dimensional echocardiography in assessment of left ventricular dssynchrony and cardiac resynchronization therapy. / H. Wang, M. Shuraih, M. Ahmad // Echocardiography. - 2012. - Vol. 29(2). - P. 192-199.

264. Ward M. L. Mechanisms underlying the impaired contractility of diabetic cardiomyopathy / M. L. Ward, D. J. Crossman // World Journal of Cardiology. -2014. - vol. 6(7). - P. 577-584.

265. Weigert J. Serum galectin-3 is elevated in obesity and negatively correlates with glycosylated hemoglobin in type 2 diabetes. / J. Weigert, M. Neumeier, J. Wanninger // J Clin Endocrinol Metab. - 2010. -№ 95(3). - P. 1404-1411.

266. Wiegerinck R. F. Schreurs R,Prinzen F.W. Pathophysiology of dyssynchrony: of squirrels and broken bones / R. F. Wiegerinck // Neth Heart J. - 2016. -- №24(1). - P. 4-10.

267. Yang F. Postconditioning of ischemic heart by intermittent ventricular pacing at the beginning of reperfusion: novel mechanisms and potential utilities in interventional cardiology settings. / F. Yang ,L. Xi // Am J Physiol Heart Circ Physiol. - 2016. - №310(1). - P.1-3.

268. Younce CW, Wang K, Kolattukudy PE. Hyperglycemia-induced cardiomyocyte death is mediated via MCP-1 production and induction of a novel zinc-finger protein MCPIP. / C.W. Younce, K. Wang, P.E. Kolattukudy // Cardiovas Res. - 2010. - №87. - P. 665-674.

269. Yu, C. M. Critical appraisal of methods to access mechanical dissynchrony [Text]/ C. M. Yu, J.Bax, J.Gorcsan //Curr.Opin.Cardiol. - 2009. Vol. -24 №1 p.18-28.

270. Zhen E.Y. Pyroglutamyl apelin-13 identified as the major apelin isoform in human plasma. / E.Y. Zhen , R.E. Higgs, J.A. Gutierrez // Anal Biochem. - 2013. - Vol.442(1). - P. 1-9.

271. 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America // Circulation. - 2016. - Vol. 134(13). - Р. 282-293.

272. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) / P. Ponikowski et al.// European Heart Journal. - Vol. 2016. - №37 (27). - P. 2129-2200.



ПЕРЕЛІК УМОВНИХ ПОЗНАЧЕНЬ

АГ - артеріальна гіпертензія;

АТ - артеріальний тиск;

АСД ДМ - автоматизованої системи діагностики диссинхроніїміокарда;

БНПГ - блокада ніжок пучка Гіса;

Гал - 3 - галектин 3;

ЕКГ - електрокардіографія;

ЕхоКГ - ехокардіографія;

ЕЦМ - екстрацелюлярний матрикс;

ДМ - диссинхронія міокарда;

ІЛ - інтерлейкін;

ММП -1 - матриксна металопротеїназа 1;

ОФІК - об'ємна фракція інтерстиціального колагену;

ФВ ЛШ - фракція викиду лівого шлуночка;

ФНП - фактор некрозу пухлини;

ХСН - хронічна серцева недостатність;

ЦД - цукровий діабет;

APEI - Aortic Pre-ejection Interval;

DT - час уповільнення кровоточу раннього діастолічного наповнення;

IVRT - час ізоволюмічного розслаблення міокарду;

LVFT - Left Ventricle Filling Time;

PPEI - Pulmonary Pre -Ejection Interval;

To-SD - середньо - квадратичне відхилення часу від початку QRS до піку систолічної швидкості.

Размещено на Allbest.ru

...